JP2019529560A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529560A5
JP2019529560A5 JP2019537047A JP2019537047A JP2019529560A5 JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5 JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
patient
csa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529560A (ja
JP7164530B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052772 external-priority patent/WO2018057776A1/en
Publication of JP2019529560A publication Critical patent/JP2019529560A/ja
Publication of JP2019529560A5 publication Critical patent/JP2019529560A5/ja
Priority to JP2022128592A priority Critical patent/JP2022160685A/ja
Application granted granted Critical
Publication of JP7164530B2 publication Critical patent/JP7164530B2/ja
Priority to JP2024153668A priority patent/JP2024174962A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537047A 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 Active JP7164530B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128592A JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US62/397,988 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US62/442,083 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US62/443,819 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US62/445,774 2017-01-13
US201762519896P 2017-06-15 2017-06-15
US62/519,896 2017-06-15
EP17306081.5 2017-08-18
EP17306081 2017-08-18
PCT/US2017/052772 WO2018057776A1 (en) 2016-09-22 2017-09-21 Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128592A Division JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Publications (3)

Publication Number Publication Date
JP2019529560A JP2019529560A (ja) 2019-10-17
JP2019529560A5 true JP2019529560A5 (https=) 2020-10-22
JP7164530B2 JP7164530B2 (ja) 2022-11-01

Family

ID=59974890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019537047A Active JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Country Status (13)

Country Link
US (1) US20220110999A1 (https=)
EP (2) EP3515465B1 (https=)
JP (3) JP7164530B2 (https=)
KR (3) KR20230006049A (https=)
CN (2) CN118203659A (https=)
AU (2) AU2017332732B2 (https=)
CA (1) CA3037499A1 (https=)
ES (1) ES2974376T3 (https=)
HU (1) HUE066662T2 (https=)
IL (2) IL265516B2 (https=)
MX (3) MX2019003235A (https=)
PL (1) PL3515465T3 (https=)
RU (1) RU2759630C2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
KR102695088B1 (ko) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
JP7836754B2 (ja) 2019-08-05 2026-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
JP2024504614A (ja) * 2021-01-14 2024-02-01 トランスレイト バイオ, インコーポレイテッド mRNAがコードする抗体を送達する方法および組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
DE60127175T2 (de) * 2000-12-21 2007-11-08 Nektar Therapeutics, San Carlos Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Similar Documents

Publication Publication Date Title
JP2019529560A5 (https=)
JP2025172841A5 (https=)
RU2019111921A (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP2022160685A5 (https=)
CN106062000B (zh) 通过施用il-4r拮抗剂治疗皮肤感染的方法
JP2021523188A5 (https=)
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
JP2017507139A5 (https=)
JP2024174962A5 (https=)
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
JP2016523863A5 (https=)
JP2017512193A5 (https=)
EP3487881B1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2017511316A5 (https=)
Choy et al. Mepolizumab (Nucala) for severe eosinophilic asthma
TW202045537A (zh) 化膿性汗腺炎的治療
JPWO2021026205A5 (https=)
JPWO2019222055A5 (https=)
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
JPWO2021195530A5 (https=)
JP2019535716A5 (https=)
HRP20191709T1 (hr) Postupci liječenja nosne polipoze davanjem antagonista il-4r
WO2021191220A1 (en) Methods for treating atopic dermatitis and related disorders